|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
3 Lagoon Drive, Suite 130, Redwood City, California 94065, US
|
|
Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide. Founded on ground-breaking neuro-immunology research from the laboratory of Professor Edgar Engleman, MD, at Stanford University, Tranquis’ novel therapeutic approach targets underlying myeloid immune cell dysfunction that has been linked to a variety of nervous system disorders. The company’s portfolio is comprised of small molecules which cross the blood-brain barrier, and the lead therapeutic candidate has demonstrated highly encouraging effects in challenging preclinical models of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s Disease (PD), and age-related cognitive impairment. Tranquis plans to initiate development in orphan neurodegenerative diseases such as ALS and FTD and later expand into more prevalent diseases such as PD and Alzheimer’s Disease. For more information, visit www.tranquis.com.
|
Tranquis Therapeutics, Inc. Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Tranquis Therapeutics, Inc. email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Tranquis Therapeutics, Inc. customer service number in your country click here to find.
Sanjay Kakkar is the CEO of Tranquis Therapeutics, Inc.. To contact Sanjay Kakkar email at [email protected], [email protected] or [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.